Results 81 to 90 of about 2,024,265 (255)

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　- Fushimi AF Registry.

Circulation Journal, 2017
BACKGROUND The current status and outcomes of direct oral anticoagulant (DOAC) use have not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world.Methods and Results:The Fushimi AF Registry is a community-based ...
Y. Yamashita, R. Uozumi, Y. Hamatani, M. Esato, Y. Chun, H. Tsuji, H. Wada, K. Hasegawa, H. Ogawa, M. Abe, S. Morita, M. Akao   +11 more
semanticscholar   +1 more source

Changing or Retaining Direct Oral Anticoagulant After Ischemic Stroke Despite Direct Oral Anticoagulant Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The optimal antithrombotic strategies for patients with atrial fibrillation who experience ischemic stroke (IS) despite direct oral anticoagulant (DOAC) therapy remain inconclusive. This study compared outcomes for patients with DOAC treatment
Shin‐Yi Lin, Yun‐Tsz Liao, Sung‐Chun Tang, Ching‐Ching Claire Lin, Chi‐Chuan Wang   +4 more
doaj   +1 more source

Therapeutic management of users with oral anticoagulant therapy

Enfermería Global, 2016
Objective: Characterize the users of oral anticoagulant therapy; to find out about treatment regimen management and to estimate International Normalized Ratio (INR) assessment costs. Methodology: Descriptive, exploratory, cross-sectional study with 83
Isaura da Conceição Cascalho Serra, Lurdes da Conceição Afonso Nobre Ribeiro, Maria Laurência Grou Parreirinha Gemito, Felismina Rosa Parreira Mendes   +3 more
doaj   +1 more source

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source

New oral anticoagulants and their reversal agents [PDF]

, 2018
Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana, Diaconu, Camelia C, Laslo, Crista L, Marcu, Dragos, Neagu, Tiberiu P, Paduraru, Dan N, Pantea Stoian, Anca, Socea, Bogdan, Socea, Laura I, Stanescu, Ana Maria Alexandra   +9 more
core   +1 more source

A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?

Vascular Health and Risk Management, 2014
Eugene Yang Division of Cardiology, University of Washington Medical Center, Seattle, WA, USA Abstract: Over the past few years, three novel oral anticoagulants, dabigatran, rivaroxaban, and apixaban, have been approved in the USA and Europe to reduce ...
Yang E
doaj  

Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis

Research and Practice in Thrombosis and Haemostasis, 2020
Background There is limited information on real‐world practice versus current clinical practice guidelines for oral anticoagulant reversal before emergency surgery.
Jerrold H. Levy, Jean M. Connors, Marie E. Steiner, James Douketis, Alex C. Spyropoulos   +4 more
doaj   +1 more source

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands

Thrombosis Journal, 2018
BackgroundIn 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) are available.
J. V. D. Heuvel, J. M. V. D. Heuvel, A. Hövels, H. Büller, A. Mantel‐Teeuwisse, A. Boer, A. M. D. Zee, A. M. D. Zee   +7 more
semanticscholar   +1 more source

Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis [PDF]

, 2018
Background. The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. Aim.
Aprile, Francesca, Gioia, Stefania, Merli, Manuela, Nardelli, Silvia, Nicoletti, Valeria, Pasquale, Chiara, Pentassuglio, Ilaria, Riggio, Oliviero   +7 more
core   +1 more source

Oral anticoagulant therapy related to oral surgery procedures [PDF]

Sanamed, 2011
Today there must be established protocol in oral surgery treatment for the patients which are under anticoagulant treatment via oral (ATO). This is due to danger of the possible complications and also for increased demand for hospital treatment of these ...
Knežević Milan, Petrović Dragan, Jović Nebojša, Bosch Carlos   +3 more
doaj